QC
ELDN icon

Quadrature Capital’s Eledon Pharmaceuticals ELDN Stock Holding History

Quadrature Capital’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-106,014
Closed -$160K – 1511
2025
Q4 		$160K Buy
106,014
+78,914
+291% +$188K ﹤0.01% 1014
2025
Q3 		$70.3K Sell
27,100
-1,958
-7% -$5.72K ﹤0.01% 927
2025
Q2 		$78.6K Buy
+29,058
New +$87.2K ﹤0.01% 911

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Quadrature Capital's ELDN Position: Q1 2026 in Review

Quadrature Capital sold out of Eledon Pharmaceuticals (ELDN) in Q1 2026, closing a stake of 106,014 shares — an estimated $160K sold.

Quadrature Capital first reported a position in ELDN in Q2 2025 and held it in 3 quarters. The position peaked at $160K in Q4 2025. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Quadrature Capital reported no remaining Eledon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 106,014 Eledon Pharmaceuticals shares in Q1 2026, an estimated $160K.
  • Quadrature Capital first reported a position in Eledon Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Quadrature Capital's Eledon Pharmaceuticals position peaked at $160K in Q4 2025.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.